Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US-2015183825-A1 · Jul 2, 2015 · US
US9604919B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9604919-B2 |
| Application number | US-201314070306-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 1, 2013 |
| Priority date | Nov 1, 2012 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are crystalline α, α-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the α, α-disubstituted amino acids and their salts; methods of making these, and methods of using these.
Opening claim text (preview).
What is claimed is: 1. A crystalline salt of a compound of Formula (I): wherein: R 1 is C 1 -C 3 alkyl, C 1 -C 3 deuteroalkyl, or C 1 -C 3 haloalkyl; * is a stereocenter; n is an integer from 3 to 11; R 2 is 9-Fluorenylmethoxycarbonyl (Fmoc); and R 3 is —H; and wherein the salt is a cyclic amine salt. 2. The crystalline salt of claim 1 , wherein R 1 is C 1 -C 3 alkyl. 3. The crystalline salt of claim 1 , wherein R 1 is methyl. 4. The crystalline salt of claim 1 , wherein n is selected from the group consisting of: 3 and 6. 5. The crystalline salt of any one of claims 1 - 3 and 4 , wherein the stereocenter * is (S). 6. The crystalline salt of any one of claims 1 - 3 and 4 , wherein the stereocenter * is (R). 7. The crystalline salt of claim 1 , having a chemical purity ranging from about 90% to 100%. 8. The crystalline salt of claim 1 , having an optical purity ranging from about 90% to 100%. 9. The crystalline salt of claim 1 , having an optical purity ranging from about 95% to 100%. 10. The crystalline salt of claim 1 , having an enantiomeric excess ranging from about 90% to 100%. 11. The crystalline salt of claim 1 , having an enantiomeric excess ranging from about 95% to 100%. 12. The crystalline salt of claim 1 , wherein the compound has a Formula (IIa): 13. The crystalline salt of claim 12 , wherein the crystalline salt has an enantiomeric excess of about 95% to 100%. 14. The crystalline salt of claim 1 , wherein the compound has a Formula (IIb): 15. The crystalline salt of claim 14 , wherein the crystalline salt has an enantiomeric excess of about 95% to 100%. 16. The crystalline salt of claim 1 , wherein the compound has a Formula (Ma): 17. The crystalline salt of claim 16 , wherein the compound or its crystalline salt has an enantiomeric excess of about 95% to 100%. 18. The crystalline salt of claim 1 , wherein the compound has a Formula (IIIb): 19. The crystalline salt of claim 18 , wherein the crystalline salt has an enantiomeric excess of about 95% to 100%. 20. The crystalline salt of claim 1 , wherein n is 3. 21. The crystalline salt of claim 1 , wherein the cyclic amine is selected from a group consisting of cyclopropylamine, cyclobutylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, and cyclooctylamine. 22. The crystalline salt of claim 1 , wherein the cyclic amine is cyclohexylamine. 23. A method of making a peptide, the method comprising reacting the crystalline salt of claim 1 with an amino acid building block in presence of a coupling agent, thereby forming a peptide bond. 24. The method of claim 23 , wherein the peptide comprises an α-helix. 25. The method of claim 23 , further comprising crosslinking a pair of terminal alkene side chains of at least two amino acids of the peptide. 26. The method of claim 25 , wherein the crosslinking comprises a metal-catalyzed olefin metathesis reaction.
with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
Separation; Purification; Stabilisation; Use of additives · CPC title
Optical isomers · CPC title
Chemistry & Metallurgy · mapped topic
to carbon atoms of hydrocarbon radicals substituted by carboxyl groups · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.